NICHOLAS BEYDA to Echinocandins
This is a "connection" page, showing publications NICHOLAS BEYDA has written about Echinocandins.
Connection Strength
2.141
-
Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata. Microbiol Spectr. 2022 02 23; 10(1):e0183721.
Score: 0.762
-
Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
Score: 0.482
-
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1086-96.
Score: 0.393
-
Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 09; 14:58-64.
Score: 0.145
-
Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr; 349(4):316-20.
Score: 0.119
-
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
Score: 0.112
-
Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species. Pharmacotherapy. 2023 06; 43(6):466-472.
Score: 0.052
-
Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis. Eur J Clin Microbiol Infect Dis. 2022 Oct; 41(10):1207-1213.
Score: 0.049
-
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
Score: 0.028